Top Story

Biomarkers may guide personalized therapy for castration-resistant prostate cancer

June 27, 2017

Assessment of androgen receptor gene status in plasma DNA identified patients with castration-resistant prostate cancer with worse outcomes to standard therapy, according to a multi-institution correlative biomarker study.

Standard treatment for castration-resistant prostate cancer involves inhibition of androgen receptor signaling with abiraterone (Zytiga, Janssen) or enzalutamide (Xtandi; Astellas, Medivation).

In the Journals

Women lack education on harms, benefits of breast cancer screening

June 27, 2017
Women are more likely to know of the benefits of mammography screening, but are not aware of the potential harms, indicating that they lack balanced information from…

St. Jude Children’s Research Hospital named nation’s best for pediatric cancer

June 27, 2017
St. Jude Children’s Research Hospital has been named the best hospital in the nation for children with cancer. The institution tops U.S. News & World

Multimodal therapy eliminates detectable disease in early metastatic prostate cancer

June 27, 2017
Aggressive multimodal therapy appeared to eliminate all detectable disease among certain patients with early metastatic prostate cancer, according to study results…
Meeting News

Nephrectomy status does not affect benefits seen with cabozantinib in renal cell carcinoma

June 26, 2017
CHICAGO — Cabozantinib improved PFS, objective response rate and OS compared with everolimus among patients with advanced renal cell carcinoma regardless of…
More News Headlines »

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
Meeting News

VIDEO: Results from MONALEESA-2 represent ‘exciting update’ for metastatic breast cancer

June 18, 2017
More »


The Identification and Management of Immune-related Adverse Events in Patients with Cancer: Practice Essentials for Emergency Medicine Providers

This activity is supported by an educational grant from Bristol-Myers Squibb.

The incorporation of immunotherapies, especially the immune checkpoint inhibitors, into treatment regimens for patients…
More »
Current Issues
View the Current Issue
HemOnc Today